HOLX - Hologic, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
37.95
-0.21 (-0.55%)
As of 12:42PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close38.16
Open38.03
Bid37.93 x 1400
Ask37.94 x 900
Day's Range37.85 - 38.25
52 Week Range35.10 - 45.09
Volume1,536,338
Avg. Volume2,084,748
Market Cap10.327B
Beta0.91
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • MARKETS: Recessions are all about the Fed—yield curve flattening is only a side effect
    Yahoo Finance Video15 days ago

    MARKETS: Recessions are all about the Fed—yield curve flattening is only a side effect

    Yahoo Finance's Jared Blikre joins Seana Smith from the floor of the New York Stock Exchange to discuss the latest market moves a day after the 10-year yield breaches 3.0% and the yield curve widened.

  • Hologic CEO on innovating in women's health
    Fox Business Videos16 days ago

    Hologic CEO on innovating in women's health

    Hologic CEO Steve MacMillan on the technological innovations in women's health, international growth, the potential impact of tariffs, acquisitions and efforts in Congress to repeal the medical device tax.

  • MARKETS: Here's why tech stocks are getting whacked again
    Yahoo Finance Video18 days ago

    MARKETS: Here's why tech stocks are getting whacked again

    Yahoo Finance's Jared Blikre joins Dion Rabouin from the floor of the New York Stock Exchange to discuss the latest market moves, as the tech sector is the worst sector performer in the S&P 500, while telecom and energy and financials are in the green.

  • MARKETS: Barclays' 5.2% GDP call is way too high—watch the benchmark revisions
    Yahoo Finance Video22 days ago

    MARKETS: Barclays' 5.2% GDP call is way too high—watch the benchmark revisions

    Yahoo Finance's Jared Blikre joins Seana Smith from the floor of the New York Stock Exchange to discuss the latest market moves ahead of Friday's highly anticipated Q2 GDP report due at 8:30 am ET.

  • Hologic Launches Fluent Fluid Management System, Widens Suite
    Zacks5 hours ago

    Hologic Launches Fluent Fluid Management System, Widens Suite

    Hologic (HOLX) adopts initiatives to boost the GYN Surgical segment.

  • 7 Bargain Stocks in Today's Pricey Market
    Kiplinger3 days ago

    7 Bargain Stocks in Today's Pricey Market

    Investors can rummage through the cheapie bin, looking for stocks with ultralow price-earnings ratios. But buying so-called deep value stocks isn't for the faint of heart: Their shares tend to be inexpensive because of a downturn in their business, and they may not rebound soon. Yet bargain hunters aren't entirely out of luck. Banks and other financial firms, for instance, trade at an average 36% discount to Standard & Poor's 500-stock index, based on the stocks' book value (assets minus liabilities), according to Bank of America Merrill Lynch. Some media companies also look inexpensive, along with technology firms that aren't as pricey as the stars of the tech world but still have strong prospects. The following seven stocks are bargains you can bet on for the long term. Our picks are profitable and leaders in their fields, but their shares trade at reasonable prices because of pressures in their industry or company-specific challenges. Eventually, we think those issues will subside. And for now, investors can buy these stocks at an attractive discount to the broad market or to industry averages. That should help set up strong returns, even if the stocks' prices rise only enough to get back to long-term average valuations. SEE ALSO: The 10 Best Stocks for GOP Tax Reform

  • Associated Press4 days ago

    Nielsen and Sysco climb while VF and Dycom slip

    Stocks that moved substantially or traded heavily Monday: VF Corp., down $3.47 to $92.82 The clothing company said it will make its denim business a separate company and focus on activewear and outdoor ...

  • MarketWatch4 days ago

    Hologic's stock drops after suspension of marketing of Vitalia TempSure device

    Shares of Hologic Inc. (holx) fell 2.9% in premarket trade Monday, after the company said its Cynosure division will suspend marketing and distribution of its Vitalia TempSure device for heating of vaginal tissue, while it considers the Food and Drug Administration's concerns over "vaginal rejuvenation" procedures using energy-based devices. Cynosure received a letter from the FDA relating to its MonaLisa Touch laser, but although the letter didn't mention Vitalia, has elected to consider the concerns and is asking customers to return purchased devices.

  • Hologic’s Medical Aesthetics Segment: Revenues Up in Fiscal Q3
    Market Realist10 days ago

    Hologic’s Medical Aesthetics Segment: Revenues Up in Fiscal Q3

    In the fiscal third quarter, Hologic (HOLX) reported revenues of ~$91.7 million for its Medical Aesthetics segment. This is a YoY (year-over-year) decline of 18.0% on a constant currency basis. However, the business reported a sequential rise in revenues in the fiscal third quarter. 

  • Hologic’s GYN Surgical Business Grew in Fiscal Q3 2018
    Market Realist10 days ago

    Hologic’s GYN Surgical Business Grew in Fiscal Q3 2018

    In the fiscal third quarter, Hologic (HOLX) reported revenues of ~$107.7 million for its GYN Surgical segment. This is a YoY (year-over-year) rise of 0.3% on a constant currency basis. Hologic expects its GYN Surgical business to witness significant improvement in the fiscal fourth quarter. 

  • Diagnostics Business Emerges as a Key Growth Driver in Fiscal Q3
    Market Realist11 days ago

    Diagnostics Business Emerges as a Key Growth Driver in Fiscal Q3

    In the fiscal third quarter, Hologic (HOLX) reported revenues of ~$294.3 million for its Diagnostics segment. This represents a YoY (year-over-year) increase of 2.3% on a constant currency basis. 

  • A Look at Hologic’s Acquisition of Faxitron Bioptics
    Market Realist11 days ago

    A Look at Hologic’s Acquisition of Faxitron Bioptics

    Hologic’s (HOLX) global Breast Health segment derives a significant portion of its revenues from new products and services, which complement the company’s Genius 3D mammography platform. This acquisition has added innovative products and solutions to Hologic’s portfolio. Faxitron Bioptic’s distribution efforts focus on pathologists and breast surgeons, which are also targeted by Hologic’s Breast Health team for mammography systems.

  • Hologic Expects Robust Earnings Growth for Fiscal 2018
    Market Realist11 days ago

    Hologic Expects Robust Earnings Growth for Fiscal 2018

    In its fiscal third-quarter conference call, Hologic (HOLX) narrowed the projected range of its fiscal 2018 EPS from $2.22–$2.27 to $2.24–$2.26. Considering the midpoint of the updated EPS guidance range, the company expects YoY (year-over-year) EPS growth of ~10.8% for fiscal 2018. 

  • Hologic Raised Its Revenue Guidance for Fiscal 2018
    Market Realist14 days ago

    Hologic Raised Its Revenue Guidance for Fiscal 2018

    During its fiscal third quarter conference call, Hologic (HOLX) raised its fiscal 2018 non-GAAP revenue guidance from $3.18 billion–$3.21 billion to ~$3.21 billion–$3.22 billion. So, its YoY (year-over-year) reported revenue growth rate for fiscal 2018 is expected to be 4.8%–5.3%, higher than the previously projected range of 4.0%–4.9%. 

  • Analysts’ Recommendations for Hologic and Its Peers in August
    Market Realist14 days ago

    Analysts’ Recommendations for Hologic and Its Peers in August

    In the fiscal third quarter, Hologic reported non-GAAP EPS of ~$0.58, which was a YoY rise of 16.0%. Hologic surpassed its revenue and EPS guidance for the fiscal third quarter. Hologic’s Diagnostics business posted a recovery compared to the fiscal second quarter, and its Surgical business has posted gradual improvement since the fiscal first quarter.

  • Thomson Reuters StreetEvents15 days ago

    Edited Transcript of HOLX earnings conference call or presentation 31-Jul-18 8:30pm GMT

    Q3 2018 Hologic Inc Earnings Call

  • Investor's Business Daily16 days ago

    This Medtech Beat Quarterly Views — So Why Is It Toppling?

    Hologic stock toppled below a buy point Wednesday as investors digested a packed quarter that included the exit of a key executive to Agilent and lower-than-expected quarterly guidance.

  • Hologic’s Strong Q3 2018 Results Beat Estimates and Guidance
    Market Realist16 days ago

    Hologic’s Strong Q3 2018 Results Beat Estimates and Guidance

    Hologic's Strong Q3 2018 Results Beat Estimates and GuidanceHologic posts its Q3 2018 earnings results

  • Hologic (HOLX) Beats Earnings and Revenue Estimates in Q3
    Zacks16 days ago

    Hologic (HOLX) Beats Earnings and Revenue Estimates in Q3

    Solid growth at Hologic's (HOLX) Breast Health and international business drives top line in Q3.

  • MarketWatch17 days ago

    Hologic shares rise after company tops quarterly expectations; CFO departs for Agilent

    Shares of Hologic Inc. (holx) rose 2% late Tuesday after the medical technology company reported better-than-expected fiscal third-quarter earnings and sales. Hologic said it earned $113 million, or 41 cents a share, in the quarter, compared with $60 million, or 21 cents a share, a year ago. Hologic also raised its revenue and EPS guidance for fiscal 2018, saying it expect sales between $3.205 and $3.22 billion for the year, compared with a previous guidance of sales between $3.18 billion and $3.21 billion, and called for adjusted EPS between $2.24 and $2.26 for the year, from a previous guidance of an adjusted EPS between $2.22 and $2.27.

  • Associated Press17 days ago

    Hologic: Fiscal 3Q Earnings Snapshot

    On a per-share basis, the Marlborough, Massachusetts-based company said it had profit of 41 cents. Earnings, adjusted for one-time gains and costs, were 58 cents per share. The results topped Wall Street ...

  • What to Expect from Hologic’s Fiscal Third-Quarter Results
    Market Realist17 days ago

    What to Expect from Hologic’s Fiscal Third-Quarter Results

    Hologic plans to release its fiscal third-quarter results on July 31 after markets close. The company exceeded its sales estimates in the second quarter of 2018. In the second quarter of 2018, Hologic registered sales of $789.3 million, up ~10.3% on a YoY (year-over-year) basis.

  • Benzinga17 days ago

    Q3 Earnings Outlook For Hologic

    On Tuesday, Hologic (NASDAQ: HOLX ) will release its latest earnings report. Check out Benzinga's report to understand the earnings report's implications. Earnings and Revenue Analysts predict Hologic ...

  • What Analysts Recommend for Hologic ahead of Third-Quarter Results
    Market Realist17 days ago

    What Analysts Recommend for Hologic ahead of Third-Quarter Results

    Hologic (HOLX), a leading women’s health technology player, will release its fiscal third-quarter earnings results on July 31 after markets close. The stock fell more than 9% following the results. Many analysts covering Hologic cut their target prices on HOLX stock in the following days. As of July 30, Reuters reported that of the 19 analysts covering Hologic, ~63% have a “buy” or “strong buy” rating on HOLX stock.

  • Medical Product Stock Earnings on Jul 31: HOLX, NUVA, QSII
    Zacks18 days ago

    Medical Product Stock Earnings on Jul 31: HOLX, NUVA, QSII

    Let's take a look at the factors that are likely to influence the earnings results of a few MedTech bigwigs within the broader Medical universe.